PMID- 34811696
OWN - NLM
STAT- MEDLINE
DCOM- 20220318
LR  - 20220318
IS  - 1699-3055 (Electronic)
IS  - 1699-048X (Linking)
VI  - 24
IP  - 3
DP  - 2022 Mar
TI  - Human umbilical cord mesenchymal stem cell-derived exosomes carrying 
      hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting 
      Galectin-3.
PG  - 517-531
LID - 10.1007/s12094-021-02705-7 [doi]
AB  - BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal 
      malignant tumors of the digestive system. Many patients are diagnosed at an 
      advanced stage and lose eligibility for surgery. Moreover, there are few 
      effective methods for treating pancreatic ductal cell carcinoma. Increasing 
      attention has been given to microRNAs (miRNAs) and their regulatory roles in 
      tumor progression. In this study, we investigated the effects of exosomes 
      extracted from human umbilical cord mesenchymal stem cells (HUCMSCs) carrying 
      hsa-miRNA-128-3p on pancreatic cancer cells. METHODS: Based on existing 
      experimental and database information, we selected Galectin-3, which is 
      associated with pancreatic cancer, and the corresponding upstream 
      hsa-miRNA-128-3p. We extracted HUCMSCs from a fresh umbilical cord, 
      hsa-miRNA-128-3p was transfected into HUCMSCs, and exosomes containing 
      hsa-miRNA-128-3p were extracted and collected. The effect of exosomes rich in 
      hsa-miRNA-128-3p on pancreatic cancer cells was analyzed. RESULTS: The expression 
      of Galectin-3 in normal pancreatic duct epithelial cells was significantly lower 
      than that in PDAC cell lines. We successfully extracted HUCMSCs from the 
      umbilical cord and transfected hsa-miRNA-128-3p into HUCMSCs. Then we 
      demonstrated that HUCMSC-derived exosomes with hsa-miRNA-128-3p could suppress 
      the proliferation, invasion, and migration of PANC-1 cells in vitro by targeting 
      Galectin-3. CONCLUSION: Hsa-miRNA-128-3p could be considered as a potential 
      therapy for pancreatic cancer. We provided a new idea for targeted therapy of 
      PDAC.
CI  - (c) 2021. Federacion de Sociedades Espanolas de Oncologia (FESEO).
FAU - Xie, X
AU  - Xie X
AD  - Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong 
      University, Nantong, 226001, Jiangsu, China.
FAU - Ji, J
AU  - Ji J
AD  - Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong 
      University, Nantong, 226001, Jiangsu, China.
FAU - Chen, X
AU  - Chen X
AD  - Office of Infection Management, Affiliated Hospital of Nantong University, 
      Nantong, 226001, Jiangsu, China.
FAU - Xu, W
AU  - Xu W
AD  - Department of Gastroenterology, Second People's Hospital of Nantong, Nantong, 
      226001, China.
FAU - Chen, H
AU  - Chen H
AD  - Office of Infection Management, Affiliated Hospital of Nantong University, 
      Nantong, 226001, Jiangsu, China.
FAU - Zhu, S
AU  - Zhu S
AD  - Medical School of Nantong University Oral Medicine, Nantong, 226001, Jiangsu, 
      China.
FAU - Wu, J
AU  - Wu J
AD  - Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong 
      University, Nantong, 226001, Jiangsu, China.
FAU - Wu, Y
AU  - Wu Y
AD  - Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong 
      University, Nantong, 226001, Jiangsu, China.
FAU - Sun, Y
AU  - Sun Y
AD  - Blood Center of Jiangsu Province, Nanjing, 210000, Jiangsu, China.
FAU - Sai, W
AU  - Sai W
AD  - Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, 
      Nantong, 226001, Jiangsu, China.
FAU - Liu, Z
AU  - Liu Z
AD  - Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong 
      University, Nantong, 226001, Jiangsu, China.
FAU - Xiao, M
AU  - Xiao M
AUID- ORCID: 0000-0003-3372-1069
AD  - Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong 
      University, Nantong, 226001, Jiangsu, China. xmb73@163.com.
AD  - Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, 
      Nantong, 226001, Jiangsu, China. xmb73@163.com.
FAU - Bao, B
AU  - Bao B
AD  - Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong 
      University, Nantong, 226001, Jiangsu, China. Bamboo1971@126.com.
LA  - eng
GR  - BK20211105/Natural Science Foundation of Jiangsu Province/
GR  - BE2019692/jiangsu provincial key research and development program/
GR  - 2019M661909/postdoctoral research foundation of china/
GR  - H2019072/the health project of jiangsu province/
GR  - MSZ20076/social development foundation of nantong city/
GR  - JCZ20065/social development foundation of nantong city/
GR  - MS12020018/social development foundation of nantong city/
GR  - MSZ19177/social development foundation of nantong city/
PT  - Journal Article
DEP - 20211123
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
RN  - 0 (Galectin 3)
SB  - IM
MH  - Carcinoma, Pancreatic Ductal/*pathology
MH  - Exosomes/*physiology
MH  - Galectin 3/*physiology
MH  - Humans
MH  - Mesenchymal Stem Cells/*ultrastructure
MH  - Pancreatic Neoplasms/*pathology
MH  - Tumor Cells, Cultured
MH  - Umbilical Cord/*cytology
OTO - NOTNLM
OT  - Exosome
OT  - Galectin-3
OT  - Hsa-miRNA-128-3p
OT  - Human umbilical cord mesenchymal stem cells
OT  - Pancreatic ductal cell carcinoma
EDAT- 2021/11/24 06:00
MHDA- 2022/03/19 06:00
CRDT- 2021/11/23 06:41
PHST- 2021/06/22 00:00 [received]
PHST- 2021/08/31 00:00 [accepted]
PHST- 2021/11/24 06:00 [pubmed]
PHST- 2022/03/19 06:00 [medline]
PHST- 2021/11/23 06:41 [entrez]
AID - 10.1007/s12094-021-02705-7 [pii]
AID - 10.1007/s12094-021-02705-7 [doi]
PST - ppublish
SO  - Clin Transl Oncol. 2022 Mar;24(3):517-531. doi: 10.1007/s12094-021-02705-7. Epub 
      2021 Nov 23.